pelacarsen 80 mg s.c
pelacarsen 80 mg s.c: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Novartis AG (NVS)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Novartis AG (NVS) | Phase 3 |
Clinical Trials (1)
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Reduction of the Rate of Lipoprotein Apheresis After Treatment With Pelacarsen (TQJ230) Compared to Placebo in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease Undergoing Weekly Lipoprotein Apheresis in Germany
Frequently asked questions
Who is developing pelacarsen 80 mg s.c?
pelacarsen 80 mg s.c is being developed by Novartis AG.
How many clinical trials involve pelacarsen 80 mg s.c?
BioSniper tracks 1 clinical trial involving pelacarsen 80 mg s.c.
Analyze Novartis AG & pelacarsen 80 mg s.c with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company